Skip to main content

Table 1 Sample description

From: Discriminative potential of exhaled breath condensate biomarkers with respect to chronic obstructive pulmonary disease

Variable

No COPD n = 279

COPD n = 21

Total n = 300

p-value

Gender, women, n (%)

141 (50.5)

10 (47.6)

151 (50.3)

0.07

Mean age, years, m (SD)

52.2 (5.3)

53.5 (5.4)

52.3 (5.3)

0.22

Age category, n (%)

 40–45

38 (13.6)

2 (9.5)

40 (13.3)

 

 45–50

43 (15.4)

2 (9.5)

45 (15.0)

 

 50–55

91 (32.6)

7 (33.3)

98 (32.7)

 

 55–60

98 (35.1)

8 (38.1)

106 (35.3)

 

 60 + 

9 (3.2)

2 (9.5)

11 (3.7)

0.55

BMI (kg/m2), m (SD)

26.0 (4.3)

25.3 (4.4)

25.9 (4.3)

0.67

Ethnicity, n (%)

 Caucasian

225 (80.6)

17 (81.0)

242 (80.7)

 

 African

44 (15.8)

4 (19.0)

48 (16.0)

 

 Other

4 (1.4)

0 (0.0)

4 (1.3)

0.84

Smoking category, n (%)

 Non smoker

147 (52.7)

7 (33.3)

154 (51.3)

 

 Current smoker

95 (34.1)

13 (61.9)

108 (36.0)

 

 Ex-smoker

37 (13.3)

1 (4.8)

38 (12.7)

0.04

Tobacco exposure, pack-years, m (SD)

14.8 (14.6)

21.5 (17.2)

15.4 (14.9)

0.11

Occupation, n (%)

   

0.91

 Station agent

123 (44.1)

9 (42.9)

132 (44.0)

 

 Locomotive operator

113 (40.5)

8 (38.1)

121 (40.3)

 

 Security guard

43 (15.4)

4 (19.0)

47 (15.7)

 

Employement duration, years, m (SD)

24.0 (6.1)

24.9 (7.5)

24.1 (6.2)

0.54

Spirometry, m (SD)

 FEV1% predicted (GLI)

99.3 (13.1)

83.6 (17.0)

98.2 (14.0)

 < 0.001

 FVC % predicted (GLI)

101.1 (12.9)

103.6 (17.8)

101.2 (13.2)

0.26

 FEV1/FVC % predicted (GLI)

98.0 (5.4)

80.0 (6.8)

96.7 (7.2)

 < 0.001

 FEF 25–75% predicted (GLI)

97.7 (28.2)

48.1 (18.7)

94.2 (30.4)

 < 0.001

COPD Stage, n (%)

 PRISm

18 (6.5)

-

-

 

 Pre-COPD: At-risk

63 (22.6)

-

-

 

 GOLD 1: Mild

-

12 (57.1)

-

 

 GOLD 2: Moderate

-

8 (38.1)

-

 

 GOLD 3: Severe

-

1 (4.8)

-

 

 GOLD 4: Very severe

-

0 (0.0)

-

 

Self declared symptoms, n (%)

 Cough

44 (15.8)

11 (52.4)

55 (18.3)

 < 0.001

 Phlegm

41 (14.7)

6 (28.6)

47 (15.7)

0.11

 Shortness of breath (Dyspnea)

40 (14.3)

4 (19.0)

44 (14.7)

0.53

 Wheezing

22 (7.9)

5 (23.8)

27 (9.0)

 < 0.01

  At least one above symptom

90 (32.2)

12 (57.1)

102 (34.0)

0.01

 Mean number symptoms above, m (SD)

0.5 (0.9)

1.2 (1.4)

0.6 (1.0)

0.03

 At least one COPD symptom exacerbation

-

7 (33.3)

-

 

Medical history, n (%)

 Asthma

27 (9.7)

3 (14.3)

30 (10.0)

0.42

 Bronchitis

7 (2.5)

1 (4.8)

8 (2.7)

0.45

 COPD

0 (0.0)

2 (9.5)

2 (0.7)

0.44

 Emphyzema

3 (1.1)

2 (9.5)

5 (1.7)

 < 0.01

 Eczema

56 (20.1)

3 (14.3)

59 (19.7)

0.04

 Pollen Allergies

60 (21.5)

6 (28.6)

66 (22.0)

0.78

  1. Abbreviations: BMI body mass index, COPD Chronic obstructive pulmonary disease, FEF 25–75% Forced expiratory flow during the middle half of the FVC, FEV1 forced expiratory volume in one second, FVC forced vital capacity, GOLD Global initiative for obstructive lung disease, PRISm preserved ratio abnormal spirometry, SD standard deviation
  2. Values shown are mean (SD) or number (%) of subjects where appropriate
  3. For definitions of GOLD stage and PRISm refer to the methods section
  4. Associations with a p-value of < 0.05 are bolded